|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 01/20/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
USDA/APHIS Agricultural Biotechnology Regulations
Coexistence of Production Systems
Biomass Crop Assistance Program
Funding
H.R.2112: Consolidated and Further Continuing Appropriations Act of 2012
Farm Bill Reauthorization
EPA Regulations on Agricultural Biotechnology
EPA Notice on PIP Data Requirements
Reauthorization and Implementation of Pesticide Registration Improvement Act
Biotechnology Stewardship
International Regulatory Synchronization
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
Labeling
FDA Approval
S. 1717: Prevention of Escapement of Genetically Altered Salmon in the United States Act of 2011
H.R.2112: Consolidated and Further Continuing Appropriations Act of 2012
Amendment to Restrict FDA Approval of GE Salmon
Export Registrations for Products with Expired Patents
Labeling of Genetically Engineered Crops
U.S. Government Policy
TransPacific Partnership
Sanitary and Phytosanitary Issues
Adventitious Presence (Low Level Presence)
U.S. Low Level Presence Policy
Funding for the USDA (Office of General Counsel , Biotechnologies Regulatory Services (BRS), Animal Care & Veterinary Services (APHIS), Trade Activities (Office of the Secretary & Food Safety Inspection Service), Agriculture Research Service, Biofuels, Foreign Agriculture Service)
H.R.2112: Consolidated and Further Continuing Appropriations Act of 2012
Foreign Agricultural Biotechnology Laws and Regulations
Low-Level Presence Foreign Government Policies
China Biotechnology Regulations
Discussions with EU on Animal Cloning
APEC Agricultural Biotechnology Discussions
EU Biotechnology Bilateral Discussions
Mexico Biotechnology Bilateral Discussions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Environmental Protection Agency (EPA),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
Labeling
FDA Approval
S. 1717: Prevention of Escapement of Genetically Altered Salmon in the United States Act of 2012
H.R.2112: Consolidated and Further Continuing Appropriations Act of 2012
Amendment to Restrict FDA Approval of GE Salmon
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
Funding for the USDA (Office of General Counsel , Biotechnologies Regulatory Services (BRS), Animal Care & Veterinary Services (APHIS), Trade Activities (Office of the Secretary & Food Safety Inspection Service), Agriculture Research Service, Biofuels, Foreign Agriculture Service)
H.R.2112: Consolidated and Further Continuing Appropriations Act of 2012
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary
Medicine, Scientific Infrastructure)
H..R.2112: Consolidated and Further Continuing Appropriations Act of 2012
Funding for Centers for Disease Control and Prevention Vaccine Programs
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
Funding for National Institutes of Health
Cures Acceleration Network
National Center for Advancing Translational Sciences
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations for FY 2012
Funding for Biofuels
H.R. 2219: Department of Defense Appropriations Act for FY 2012
H.R. 2354: The Energy and Water Appropriations Act for 2012
Funding for Bio-based Products
H.R. 2219: Department of Defense Appropriations Act for FY 2012
H.R. 2354: The Energy and Water Appropriations Act for 2012
Funding for Biomass Crop Assistance Program
H.R. 2112: Consolidated and Further Continuing Appropriations Act of 2012
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Environmental Protection Agency (EPA),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Matt |
Carr |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Cartier |
Esham |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Sara |
Radcliffe |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
DelMonte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
Climate Change Benefits of Biofuels and Bio-based Products
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Biogenic Carbon Emissions Accounting
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
O'Brien |
|
|
|
Matt |
Carr |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
Implementation of H.R. 1249: The America Invents Act of 2011
World Trade Organization Special 301 Submissions
China Issues
Finland Issues
Russia Issues
Genetic Resource Patent Disclosure Requirement
World Intellectual Property Organization
DNA Patenting and Licensing
Rep. Wasserman Schultz Amendment to H.R. 1249: The America Invents Act of 2011
Bayh-Dole Act/Tech Transfer
Bayh-Dole Act/Tech Transfer
Commercialization of Federally Funded Research Initiative
Domestic Manufacturing Requirement
International IP Patent Law Harmonization
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), State - Dept of (DOS), U.S. Trade Representative (USTR),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lila |
Feisee |
|
|
|
Hans |
Sauer |
|
|
|
Matthew |
Schumaker |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Roy |
Zwahlen |
|
|
|
Charles |
Fritts |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
USDA/APHIS Agricultural Biotechnology Regulations
Coexistence of Production Systems
Genetically Engineered (GE) Animals
Labeling
FDA Approval
S. 1717: Prevention of Escapement of Genetically Altered Salmon in the United States Act of 2012
H.R. 2112: Consolidated and Further Continuing Appropriations Act of 2012
Amendment to Restrict FDA Approval of GE Salmon
Drug Importation
H.R. 2112: Consolidated and Further Continuing Appropriations Act of 2012
Labeling of Genetically Engineered Crops
U.S. Government Policy
Drug Safety and Review
FDA Globalization Act (Discussion Draft)
Prescription Drug User Fee Act (PDUFA) Reauthorization
Regulatory Reforms for Innovative Products
TREAT Act (Senate Discussion Draft)
E-Pedigree and Anti-Counterfeiting
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
H.R.2112: Consolidated and Further Continuing Appropriations Act of 2012
Drug Shortages
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Sandra |
Dennis |
|
|
|
Melissa |
Bowie |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Alyson |
Pusey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Climate Change Benefits of Biofuels and Bio-based Products
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Biogenic Carbon Emissions Accounting
Biofuels
Next Generation Incentives : Farm Bill Reauthorization
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Investment Tax Credit Options
Economic Growth Impact/Potential of Advanced Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
DOE Loan Guarantees and Grants under the Energy Policy Act of 2005 (Implementation and Funding)
Biofuels Production Tax Credit Extension
Funding for Biofuels
H.R. 2219: Department of Defense Appropriations Act for FY 2012
H.R. 2354: The Energy and Water Appropriations Act for 2012
Renewable Fuels Standard
Implementation of Energy Independence and Security Act of 2007
Regulatory Oversight
Biorefineries
Next Generation Incentive Tax Credits
Bio-based Products
Next Generation Incentives: Farm Bill Reauthorization
Expansion of DOE and USDA Loan Guarantee Programs
Tax Credit
USDA BioPreferred Program
Economic Growth Impact/Potential of Advanced Bio-based Products
Funding for Bio-based Products
H.R. 2219: Department of Defense Appropriations Act for FY 2012
H.R. 2354: The Energy and Water Appropriations Act for 2012
Renewable Chemicals
New Production Tax Credit/Revisions to Existing Tax Credits
S.847: The Safe Chemicals Act of 2011 (TSCA Reform Proposals)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, U.S. SENATE, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
Labeling
FDA Approval
S. 1717: Prevention of Escapement of Genetically Altered Salmon in the United States Act of 2011
H.R. 2112: Consolidated and Further Continuing Appropriations Act of 2012
Amendment to Restrict FDA Approval of GE Salmon
Labeling of Genetically Engineered Crops
U.S. Government Policy
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Climate Change Benefits of Biofuels and Bio-based Products
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Biogenic Carbon Emissions Accounting
Biofuels
Next Generation Incentives : Farm Bill Reauthorization
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Investment Tax Credit Options
Economic Growth Impact/Potential of Advanced Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
DOE Loan Guarantees and Grants under the Energy Policy Act of 2005 (Implementation and Funding)
Biofuels Production Tax Credit Extension
Funding for Biofuels
H.R. 2219: Department of Defense Appropriations Act for FY 2012
H.R. 2354: The Energy and Water Appropriations Act for 2012
Renewable Fuels Standard
Implementation of Energy Independence and Security Act of 2007
Regulatory Oversight
Biorefineries
Next Generation Incentive Tax Credits
Bio-based Products
Next Generation Incentives: Farm Bill Reauthorization
Expansion of DOE and USDA Loan Guarantee Programs
Tax Credit
USDA BioPreferred Program
Economic Growth Impact/Potential of Advanced Bio-based Products
Funding for Bio-based Products
H.R. 2219: Department of Defense Appropriations Act for FY 2012
H.R. 2354: The Energy and Water Appropriations Act for 2012
Renewable Chemicals
New Production Tax Credit/Revisions to Existing Tax Credits
S.847: The Safe Chemicals Act of 2011 (TSCA Reform Proposals)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
Biosimilars
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Funding for National Institutes of Health
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations for FY 2012
Funding for Centers for Disease Control and Prevention Vaccine Programs
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
Reporting of Physician Payments
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Vaccine Access/Financing
Adult Immunization Policies
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
340B Drug Pricing Program
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
HRSA Implementation of Program Changes
Federal Supply Schedule Access During Emergencies
Expanded Access to Experimental Products
Medicaid Rebates
Dual Eligibles
S 365: Budget Control Act of 2011
Drug Importation
H.R. 2112: Consolidated and Further Continuing Appropriations Act of 2012
Diagnostics and Personalized Medicine Regulation and Oversight
Therapeutic Discovery Project Tax Credit
Extension
Rare Pediatric & Tropical Disease Drug Development
Drug Safety and Review
FDA Globalization Act (Discussion Draft)
Prescription Drug User Fee Act (PDUFA) Reauthorization
Regulatory Reforms for Innovative Products
TREAT Act (Senate Discussion Draft)
E-Pedigree and Anti-Counterfeiting
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
H.R. 2112: Consolidated and Further Continuing Appropriations Act of 2012
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
Cures Acceleration Network
S. R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
National Center for Advancing Translational Sciences
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations for FY 2012
Biodefense Research, Development and Procurement
HHS Countermeasures Review
S. 1855: Pandemic and All Hazards Preparedness Act Reauthorization of 2011
Drug Shortages
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
Reimbursement for Innovative Products
Part B Physician-Administered Products
Medicare Part D Prescription Drug Program
International Biosecurity Policies
Biologics and Toxins Weapons Convention
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelly |
Mui-Lipnik |
|
|
|
Roy |
Zwahlen |
|
|
|
Sandra |
Dennis |
|
|
|
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Cartier |
Esham |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Brent |
Del Monte |
|
|
|
Alan |
Eisenberg |
|
|
|
Charles |
Fritts |
|
|
|
Alyson |
Pusey |
|
|
|
Kelly |
Cappio |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
Federal Supply Schedule Access During Emergencies
Biodefense Research, Development and Procurement
HHS Countermeasures Review
S. 1855: Pandemic and All Hazards Preparedness Act Reauthorization Act of 2011
International Biosecurity Policies
Biologics and Toxins Weapons Convention
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), State - Dept of (DOS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
Anna |
Weinstein |
|
|
|
Phyllis |
Arthur |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Sara |
Radcliffe |
|
|
|
Kelly |
Cappio |
|
|
|
Matthew |
Schumaker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations for FY 2012
Rare Pediatric & Tropical Disease Drug Development
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
Cures Acceleration Network
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2012
National Center for Advancing Translational Sciences
S.R. 1599: Departments of Labor, HHS, Education, and Related Agencies Appropriations for FY 2012
Biodefense Research, Development and Procurement
HHS Countermeasures Review
S. 1855: Pandemic and All Hazards Preparedness Act Reauthorization of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tracey |
LaTurner |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Phyllis |
Arthur |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
|
Sara |
Radcliffe |
|
|
|
Kelly |
Cappio |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Rebates
Dual Eligibles
S. 365: Budget Control Act of 2011
Reimbursement for Innovative Products
Medicare Part B Physician-Administered Products
Medicare Part D Prescription Drug Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Melissa |
Bowie |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Laurel |
Todd |
|
|
|
Andrew |
Emmett |
|
|
|
Brent |
Del Monte |
|
|
|
Alyson |
Pusey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Research & Development Tax Credit Extension
H.R. 942: American Research and Competitiveness Act of 2011
S. 1577: Greater Research Opportunities With Tax Help Act of 2011
Small Business Innovation and Research (SBIR) Program Reauthorization
S.493: SBIR/STTR Reauthorization Act of 2011
H.R. 1425: Creating Jobs Through Small Business Innovation Act of 2011
H.R. 1540: National Defense Authorization Act for FY 2012
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
Del Monte |
|
|
|
Matthew |
Schumaker |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Shareholder Reporting Threshold
S. 1824/H.R. 2167: Private Company Flexibility and Growth Act of 2011
Small Business Innovation and Research (SBIR) Program Reauthorization
S.493: SBIR/STTR Reauthorization Act of 2011
H.R. 1425: Creating Jobs Through Small Business Innovation Act of 2011
H.R. 1540: National Defense Authorization Act for FY 2012
Sarbanes Oxley Section 404 (b)
H.R. 3213: Small Company Job Growth and Regulatory Relief Act of 2011
S. 1933/H.R. 3606: Reopening American Capital Markets to Emerging Growth Companies Act of 2011
Therapeutic Discovery Project Tax Credit
Extension
Capital Formation Investment Incentives
Expansion of Exemption Under SEC Regulation A
S. 1544/H.R. 1070: The Small Company Capital Formation Act of 2011
Reform of SEC Regulation D
S. 1831/H.R. 2940: Access to Capital for Job Creators Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tooshar |
Swain |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
Del Monte |
|
|
|
Anna |
Weinstein |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biorefineries
Next Generation Incentive Tax Credits
Bio-based Products
Tax Credit
Therapeutic Discovery Project Tax Credit
Extension
Biofuels
Investment Tax Credit Options
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Biofuels Production Tax Credit Extension
Research & Development Tax Credit Extension
H.R. 942: American Research and Competitiveness Act of 2011
S. 1577: Greater Research Opportunities With Tax Help Act of 2011
Capital Formation Investment Incentives
Renewable Chemicals
New Production Tax Credit/Revisions to Existing Tax Credits
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
Schumaker |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Sarah |
Thornton Caswell |
|
|
|
Tooshar |
Swain |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Export Registrations for Products with Expired Patents
Foreign Agricultural Biotechnology Laws and Regulations
Low-Level Presence Foreign Government Policies
China Biotechnology Regulations
Discussions with EU on Animal Cloning
APEC Agricultural Biotechnology Discussions
EU Biotechnology Bilateral Discussions
Mexico Biotechnology Bilateral Discussions
Genetic Resource Patent Disclosure Requirement
World Intellectual Property Organization
TransPacific Partnership
Sanitary and Phytosanitary Issues
Data and Intellectual Property Protections for Pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), State - Dept of (DOS), Patent & Trademark Office (PTO),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
David |
Edwards |
|
|
|
Matthew |
Schumaker |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Roy |
Zwahlen |
|
|
|
Matthew |
O'Mara |
|
|
|
Ab |
Basu |
|
|
|
Brent |
Del Monte |
|
|
|
Joseph |
Damond |
|
|
|
Anna |
Weinstein |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Drug Importation
H.R. 2112: Consolidated and Further Continuing Appropriations Act of 2012
Medicaid Rebates
Dual Eligibles
S. 365: Budget Control Act of 2011
Drug Shortages
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
Reimbursement for Innovative Products
Medicare Part D Prescription Drug Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Anna |
Weinstein |
|
|
|
Sandra |
Dennis |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Melissa |
Bowie |
|
|
|
Alyson |
Pusey |
|
|
|
Laurel |
Todd |
|
|
|
Tracey |
LaTurner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |